Please wait

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Name of Issuer)

(Title of Class of Securities)

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13D 0002109116 XXXXXXXX LIVE Common Stock, $0.0001 par value 03/09/2026 true 0001855485 320703408 Calidi Biotherapeutics, Inc. 4475 EXECUTIVE DRIVE SUITE 200 SAN DIEGO CA 92121 Chellsea Cartoscelli 9165040529 2315 Capitol Avenue Sacramento CA 95816 0002109116 N Gavrilov Ognian Anguelov PF N X1 700000.00 0.00 700000.00 0.00 700000.00 N 9.8 IN Common Stock, $0.0001 par value Calidi Biotherapeutics, Inc. 4475 EXECUTIVE DRIVE SUITE 200 SAN DIEGO CA 92121 Ognian Anguelov Gavrilov 2315 Capitol Avenue, Sacramento, CA 95816 Managing Partner, Gavrilov & Brooks, 2315 Capitol Avenue, Sacramento, CA 95816 Not Applicable Not Applicable United States of America Personal Funds The Reporting Person acquired the Shares for investment purposes. The Reporting person may from time to time acquire additional shares of common stock or dispose of some or all of the shares in open market transactions, privately negotiated transactions, or otherwise. Except as set forth above, the Reporting Person currently has no plans or proposals which relate to or would result in any of the actions described in clauses a through j of item 3. 700,000 (9.8%) Sole voting power 700,000 Shared voting powered 0 Sole dispositive power 700,000 Shared dispositive power 0 None. No person other than the Reporting Person has the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the securities. Not Applicable Not Applicable Gavrilov Ognian Anguelov Ognian Anguelov Gavrilov Managing Partner 03/09/2026